Last €61.67 EUR
Change Today +0.233 / 0.38%
Volume 0.0
RV6 On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 1:21 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

charles river laboratories (RV6) Snapshot

Open
€61.55
Previous Close
€61.44
Day High
€61.99
Day Low
€60.63
52 Week High
01/27/15 - €62.77
52 Week Low
05/5/14 - €36.02
Market Cap
2.9B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
46.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHARLES RIVER LABORATORIES (RV6)

charles river laboratories (RV6) Related Bloomberg News

View More Bloomberg News

charles river laboratories (RV6) Related Businessweek News

No Related Businessweek News Found

charles river laboratories (RV6) Details

Charles River Laboratories International, Inc., together with its subsidiaries, provides research models and associated services, and outsourced preclinical services to accelerate the drug discovery and development process. It operates through two segments, Research Models and Services (RMS), and Preclinical Services (PCS). The RMS segment produces and sells research model strains, principally genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also offers a range of services to assist customers in the drug discovery and development process, which include genetically engineered models and services, insourcing solutions, discovery research services, and research animal diagnostic services; endotoxin and microbial detection products and services; and avian vaccine products and services. The PCS segment provides preclinical services, including in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. This segment offers services in the areas of bioanalysis, pharmacokinetics, and drug metabolism; toxicology; and pathology services, as well as testing of biologics and devices frequently outsourced by pharmaceutical and biotechnology companies. The company serves pharmaceutical companies, biotechnology companies, government agencies, hospitals, and academic institutions worldwide. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

7,700 Employees
Last Reported Date: 02/25/14
Founded in 1947

charles river laboratories (RV6) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.1M
Chief Financial Officer and Corporate Executi...
Total Annual Compensation: $512.2K
Corporate Executive Vice President and Presid...
Total Annual Compensation: $450.9K
Chief Scientific officer and Corporate Execut...
Total Annual Compensation: $500.5K
Chief Administrative Officer, Corporate Execu...
Total Annual Compensation: $567.5K
Compensation as of Fiscal Year 2013.

charles river laboratories (RV6) Key Developments

Charles River Laboratories Mulls Acquisitions

Charles River Laboratories International, Inc. (NYSE:CRL) intends to make acquisitions. Jim Foster, Chairman, President and Chief Executive Officer of the company said: “So we're going to look quickly at four growth drivers for the Company portfolio and geographic expansion, strategic relationships, targeted sales strategies and our efficiency initiatives. We are very serious about continuing to aggressively expand our portfolio. We're looking, first and foremost, for strategic acquisitions which are accretive and fill out the portfolio in ways that are beneficial to our clients. So we're looking -- continuing to look aggressively upstream. We're continuing to think about expanding our current therapeutic areas and moving into others. We're looking at in vitro technologies. We're looking somewhat geographically. We're always open to increasing our service and software capabilities in our EMD business. We're looking at additional models for safety assessment, whether that's mini pigs or transgenic animals or humanized animals. And we're carefully but seriously looking at growing our service and product capabilities in China. We have a research model business there that's growing very nicely with terrific profitability.” He added: “So from a strategic point of view we're looking into drive our top line through strategic acquisitions that grow the portfolio and are accretive, continued internal investment in our businesses, all of them, particularly our growth businesses. For us, it's all about share gains. We are taking share in all of our businesses. We're going to continue to be focused on that. We're going to continue to try to expand our current strategic relationships and initiate new ones, both with large pharma, small pharma and large and small biotech and hopefully increasingly with our academic colleagues. It's all about the quality of our people. We just inherited some fabulous scientists with the M&A that we did over the past six or seven months. We're very focused on getting some of the best scientists in the world, many of whom are coming from Big Pharma. And biotech we are going to continue to drive efficiency and productivity through our business and we are getting much better doing that internally without needing to use outside organizations. Capital deployment is going to be strategic acquisitions first. We're going to offset dilution from options by buying back shares and we'll obviously continue to service our debt.”

Charles River Laboratories International, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 09:30 AM

Charles River Laboratories International, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 09:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: James C. Foster, Chairman, Chief Executive Officer, President, Chairman of Executive Committee and Member of Strategic Planning & Capital Allocation Committee.

Charles River Laboratories International Announces Management Changes

Charles River Laboratories International, Inc. announced that Jrg Geller, Corporate Executive Vice President, Global Productivity and Efficiency, had announced his intention to retire in March 2015. Geoff Goldsmith, Corporate Vice President, North American Operations Optimization, will continue in his role with Charles Rivers global productivity and efficiency initiatives with support from other individuals globally.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RV6:GR €61.67 EUR +0.233

RV6 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Covance Inc $106.21 USD -0.31
Ergomed PLC 161.00 GBp 0.00
ICON PLC $56.40 USD -0.59
PAREXEL International Corp $60.96 USD -0.55
WuXi PharmaTech Cayman Inc $40.10 USD -0.61
View Industry Companies
 

Industry Analysis

RV6

Industry Average

Valuation RV6 Industry Range
Price/Earnings 27.8x
Price/Sales 2.6x
Price/Book 4.9x
Price/Cash Flow 23.0x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHARLES RIVER LABORATORIES, please visit www.criver.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.